‘Real-life’ study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis

References

• Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7. doi: 10.1056/NEJM200104053441401
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single institution historical experience. Blood 2012;119:1981–7. doi: 10.1182/blood-2011-08-358135
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. doi: 10.1056/NEJMoa022457
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Shah NP, Cortes J, Baccarani M, Bradley-Garelik MB, Dejardin D, et al. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. J Clin Oncol. 2012;30:6504.
   Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim D-W, et al. Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 36-month follow-up. Leukemia 2012;26:2197–203. doi: 10.1038/leu.2012.134
   PubMed Web of Science ®Google Scholar
• Marin D. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. Hematol Am Soc Hematol Educ Progr. 2012:115–21.
   PubMed Web of Science ®Google Scholar
• Marin D. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?. J Clin Oncol. 2014;32(5):379–84. doi: 10.1200/JCO.2013.52.9230
   PubMed Web of Science ®Google Scholar
• Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012;26:2172–5. doi: 10.1038/leu.2012.104
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37. doi: 10.1182/blood-2006-01-0092
   PubMed Web of Science ®Google Scholar
• Gabert J, Billard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of “real time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual d ase detection in leukemia – a Europe against cancer program. Leukemia 2003;17:2318–57. doi: 10.1038/sj.leu.2403135
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24:1719–24. doi: 10.1038/leu.2010.185
   PubMed Web of Science ®Google Scholar
• Cullis JO, Marks DI, Schwarer AP, Barrett AJ, Hows JM, Swirsky DM, et al. Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukaemia: a report of five cases. Br J Haematol. 1992;81:378–82. doi: 10.1111/j.1365-2141.1992.tb08243.x
   PubMed Web of Science ®Google Scholar
• Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–30. doi: 10.1200/JCO.2012.48.5797
   PubMed Web of Science ®Google Scholar
• Horn M, Glauche I, Müller MC, Hehlmann R, Hochhaus A, Loeffler M, et al. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood 2013;121(2):378–84. doi: 10.1182/blood-2012-07-441956
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118(17):4554–60. doi: 10.1182/blood-2011-04-347575
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R, Diverio D, et al. “Real-life” results of front-line treatment with imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res. 2010;34:1472–5. doi: 10.1016/j.leukres.2010.07.001
   PubMed Web of Science ®Google Scholar
• Gugliotta G, Castagnetti F, Apolinari M, Pirondi S, Cavo M, Baccarani M, et al. First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs 2014;74:627–43. doi: 10.1007/s40265-014-0207-7
   PubMed Web of Science ®Google Scholar
• Russo D, Martinelli G, Malagola M, Skert C, Soverini S, Iacobucci I, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood 2013;121(26):5138–44. doi: 10.1182/blood-2013-01-480194
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;24:2381–88. doi: 10.1200/JCO.2009.26.3087
   Web of Science ®Google Scholar
• Olshen A, Tang M, Cortes J, Gonen M, Hughes T, Branford S, et al. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica. Doi:10.3324/haematol.2014.085977
   PubMed Web of Science ®Google Scholar
• Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005;90:979–81.
   PubMed Web of Science ®Google Scholar
• Liang K-Y, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 1986;73(1):13–22. doi: 10.1093/biomet/73.1.13
   Web of Science ®Google Scholar
• Pan W. Akaike's informat ion criterion in generalized estimating equations. Biometrics 2001;57:120–5. doi: 10.1111/j.0006-341X.2001.00120.x
   PubMed Web of Science ®Google Scholar
• Cui J. QIC program and model selection in GEE analyses. Stata J. 2007;7(2):209–20.
   Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Intergroupe Francais des Leucemies Myeloides Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least two years: the prospective, multicentre, Stop IMatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35. doi: 10.1016/S1470-2045(10)70233-3
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104:2204–5. doi: 10.1182/blood-2004-04-1335
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, Arthur C, Yeung DT, Dang P, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515–22. doi: 10.1182/blood-2013-02-483750
   PubMed Web of Science ®Google Scholar
• Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A, et al. Imatinib and pegylated IFN-a2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Eur J Haematol. 2014;92(5):413–20. doi: 10.1111/ejh.12258
   PubMed Web of Science ®Google Scholar
• Mahon FX, Nicolini FE, Noël MP, Escoffre M, Charbonnier A, Rea D, et al. Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood 2013. ASH Annual Meeting Abstract 654.
   Google Scholar
• Ross MD, Hughes TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Brit J Haematol. 2014;1:3–11. doi: 10.1111/bjh.12892
   Web of Science ®Google Scholar
• Wodarz D. Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses. Proc Royal Soc Biol. 2010;277:1875–80. doi: 10.1098/rspb.2009.2179
   PubMed Web of Science ®Google Scholar
• Wodarz D. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation. Med. Hypotheses 2008;70:128–36. doi: 10.1016/j.mehy.2007.03.040
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–32. doi: 10.1056/NEJMoa030513
   PubMed Web of Science ®Google Scholar
• Malagola M, Breccia M, Skert C, Cancelli V, Soverini S, Iacobucci I, et al. Long term outcome of Ph+CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. Am J Hematol. 2014;89(2):119–24. doi: 10.1002/ajh.23593
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358–63. doi: 10.1200/JCO.2007.15.8154
   PubMed Web of Science ®Google Scholar
• Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007;13:7080–5. doi: 10.1158/1078-0432.CCR-07-0844
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Jabbour E. Tyrosine kinase inhibitors early in the disease course: lessons from chronic myelogenous leukemia. Semin Oncol. 2015;42(6):876–86. doi: 10.1053/j.seminoncol.2015.09.030
   PubMed Web of Science ®Google Scholar